Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mismatch Repair01:36

Mismatch Repair

Overview
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Unrealistic Optimism Bias01:30

Unrealistic Optimism Bias

Unrealistic optimism bias is the tendency to overestimate the likelihood of positive outcomes. This cognitive bias makes individuals believe they are less likely to experience failures, setbacks, or risks and more likely to succeed than others. For example, people may assume they are less prone to health issues, accidents, or financial struggles than their peers, even when they share similar risk factors.One key component of this bias is the above-average effect, where individuals perceive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.

The Canadian journal of cardiology·2005
Same author

Ejection fraction velocity ratio as an indicator of aortic stenosis severity.

Echocardiography (Mount Kisco, N.Y.)·2005
Same author

Precision and accuracy of the bedside examination in detecting an ejection fraction of less than 40% following acute myocardial infarction.

The Canadian journal of cardiology·2004
Same author

The number remaining at risk: an adjunct to the number needed to treat.

The Canadian journal of cardiology·2002
Same author

Reducing bedrest following arterial puncture for coronary interventional procedures--impact on vascular complications: the BAC Trial.

The Journal of invasive cardiology·2001
Same author

Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis.

Journal of the American College of Cardiology·2001

Related Experiment Video

Updated: Jul 9, 2026

Predicting the Effectiveness of Population Replacement Strategy Using Mathematical Modeling
20:36

Predicting the Effectiveness of Population Replacement Strategy Using Mathematical Modeling

Published on: July 4, 2007

The number needed to harm: is it too optimistic?

D Massel1

  • 1Department of Medicine, University of Western Ontario, London, Canada. dmassel@lhsc.on.ca

The Canadian Journal of Cardiology
|February 5, 2004
PubMed
Summary
This summary is machine-generated.

The number needed to treat (NNT) and number needed to harm (NNH) help interpret clinical trial outcomes. NNH quantifies patient harm from treatments, but may underestimate true risks.

More Related Videos

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation

Published on: September 4, 2017

An Automated Microscopic Scoring Method for the γ-H2AX Foci Assay in Human Peripheral Blood Lymphocytes
08:23

An Automated Microscopic Scoring Method for the γ-H2AX Foci Assay in Human Peripheral Blood Lymphocytes

Published on: December 25, 2021

Related Experiment Videos

Last Updated: Jul 9, 2026

Predicting the Effectiveness of Population Replacement Strategy Using Mathematical Modeling
20:36

Predicting the Effectiveness of Population Replacement Strategy Using Mathematical Modeling

Published on: July 4, 2007

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation

Published on: September 4, 2017

An Automated Microscopic Scoring Method for the γ-H2AX Foci Assay in Human Peripheral Blood Lymphocytes
08:23

An Automated Microscopic Scoring Method for the γ-H2AX Foci Assay in Human Peripheral Blood Lymphocytes

Published on: December 25, 2021

Area of Science:

  • Clinical research methodology
  • Medical statistics
  • Pharmacovigilance

Background:

  • Clinical trials assess therapeutic benefits and risks.
  • Interpreting treatment outcomes requires understanding both positive and negative effects.
  • Existing metrics like NNT focus on benefits, necessitating complementary harm assessment.

Purpose of the Study:

  • To introduce and define the number needed to harm (NNH) as a measure for adverse outcomes in clinical trials.
  • To highlight the relationship between NNH and the absolute risk increase.
  • To discuss the potential limitations of NNH in reflecting true therapeutic risks.

Main Methods:

  • Conceptual definition of NNH based on absolute risk increase.
  • Comparison of NNH with the number needed to treat (NNT).
  • Discussion of the interpretation of NNH in the context of experimental vs. control treatments.

Main Results:

  • NNH is defined as the reciprocal of the absolute risk increase.
  • NNH represents the number of patients exposed to an experimental treatment for one additional harm event.
  • NNH may present an optimistic view of treatment-related risks.

Conclusions:

  • NNH is a valuable metric for quantifying patient harm in clinical studies.
  • Understanding NNH is crucial for a balanced interpretation of treatment efficacy and safety.
  • Further consideration is needed to address the potential underestimation of risks by NNH.